Serum 25-hydroxyvitamin D concentration is associated with device-estimated sleep metrics in healthy young and early middle-aged adults
D'Agata MN., Hoopes EK., Keiser T., Patterson F., Brewer BC., Witman MA.
Prospective Study with a reported sample of 79, published in Sleep Adv (2025) — summary generated from the PubMed abstract.
Early human evidence such as case series or small samples is exploring possible benefits.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Prospective Study
- Journal
- Sleep Adv (2025)
- Reported sample size
- 79
- Source database
- Europe PMC
- PMID
- 41341996
- PMCID
- PMC12670636
- DOI
- 10.1093/sleepadvances/zpaf077
- Citations
- 1
Abstract (original English)
Study objectives We tested associations between serum 25-hydroxyvitamin D concentration ([25(OH)D]) and device-estimated sleep metrics, including sleep duration, sleep efficiency, sleep duration regularity, sleep timing regularity, and sleep regularity index (SRI), in young and early middle-aged adults (18-45 years). We also assessed the mediating effect of nighttime melatonin (urinary 6-sulfatoxymelatonin (aMT6s) excretion) on these associations. Methods Participants ( n = 79) completed 14 days of wrist actigraphy. Fasted blood sampling was performed to quantify serum [25(OH)D]. First morning void was used to quantify overnight urinary aMT6s excretion, normalized to creatinine clearance. Associations between [25(OH)D] and sleep metrics were evaluated using linear regression (model 1). Separate models adjusted for age, sex, race, and body fat % (model 2), season of testing, caffeine consumption, and education level (model 3), and device-estimated moderate-to-vigorous physical activity (model 4; n = 68). Results Serum [25(OH)D] was positively associated with sleep duration, sleep efficiency, and SRI, and negatively associated with sleep duration regularity, sleep onset timing regularity, and sleep midpoint timing regularity in model 1 (all p p p = .036). In model 3, serum [25(OH)D] remained significantly associated with all sleep metrics ( p Conclusions Serum [25(OH)D] is indepe
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Early human evidence such as case series or small samples is exploring possible benefits.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.